|
|
 |
|
|
|
|
71. Skyrocketing Prescription Drug Prices: Turning a Bad Deal into a Fair Deal. A Briefing Paper Prepared by the Majority Staff of the U.S. Senate Special Committee on Aging. David Pryor, Chairman, November 16, 1994. |
|
|
|
|
|
|
|
|
72. Wickline v State of California. 288 Cal. Reptr. 661 (Cal. Ct. App. 1986). |
|
|
|
|
|
|
|
|
73. D. Elden. Managed care liability relating to formularies and drug utilization management. Managed Healthcare Pharmacy 1: 15, 1992. |
|
|
|
|
|
|
|
|
74. PBM evolution toward risk-sharing with manufacturers. FDC ReportsThe Pink Sheet 56: T&G 3, June 20, 1994. |
|
|
|
|
|
|
|
|
75. A. Farrar-Roff. Expanding role of formularies with eye on cost, compliance and care. Pharmacy Today 1: 25, 1995. |
|
|
|
|
|
|
|
|
76. Marion Merrell Dow. Managed Care DigestLong Term Care Edition, 1994. |
|
|
|
|
|
|
|
|
77. E. Tanouye. Drug Marketers May Use Illegal Tactics to Sell. The Wall Street J., August 23, 1994. |
|
|
|
|
|
|
|
|
78. L. F. Soyka. Risks and benefits of global drug development: resource consideration. Drug Info J. 27: 1095, 1993. |
|
|
|
|
|
|
|
|
79. D. S. Hilzenrath. Cutting back on Me-too drugs. The Washington Post p. C1, C2, April 26, 1994. |
|
|
|
|
|
|
|
|
80. H. Grabowski. Medicaid Patients' access to new drugs. Health Affairs 7: 804, 1988. |
|
|
|
|
|
|
|
|
81. E. Tanouye. Bestselling drugs held off low-cost challengers in '94. The Wall Street J. January 18, 1995. |
|
|
|
|
|
|
|
|
82. P. R. Vagelos. Are prescription prices too high? Science 252: 1080, 1991. |
|
|
|
|
|
|
|
|
83. Historical Consumer Price Index for All Urban Consumers. Bureau of Labor Statistics, 1993. |
|
|
|
|
|
|
|
|
84. M. Kolassa. Reductions in Pharmaceutical Price Growth. Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, February 1993. |
|
|
|
|
|
|
|
|
85. J. Wechsler. Health reform threatens medical research. Appl. Clin. Trials 2: 12, 1993. |
|
|
|
|
|
|
|
|
86. Boston Consulting Group. The Changing Environment for U.S. Pharmaceuticals. New York, NY, April 1993. |
|
|
|
|
|
|
|
|
87. CBER will commission study to investigate declining submissions. FDC ReportsThe Pink Sheet 57: 6, January 16, 1995. |
|
|
|
|
|
|
|
|
88. J. Wechsler. Re-evaluating clinical trials: Devices, outcomes, and efficacy. Appl. Clin. Trials 2: 14, 1993. |
|
|
|
|
|
|
|
|
89. FDA being drawn into cost effectiveness field through ad oversight, Kessler says, Agency is receiving cost studies with NDAs, increasing role predicted. FDC ReportsThe Pink Sheet 55: 8, November 1, 1993. |
|
|
|
|
|
|
|
|
90. E. Lewis. Captopril use in diabetic nephropathy. New Engl. J. Med. 329: 161922, 1993. |
|
|
|
|
|
|
|
|
91. Glaxo bid for Wellcome follows SmithKline/Beecham, Bristol-Myers Squibb models. FDC ReportsThe Pink Sheet 57: 7, January 30, 1995. |
|
|
|
|
|
|
|
|
92. B. Tambi. Impact of global drug development on industry mergers, acquisitions and joint ventures. Drug Info. J. 27: 1089, 1993. |
|
|
|
|
|
|
|
|
93. T.L. Copmann and C. R. Eaton. PMA Analysis. In Development Biotechnology Medicines. Pharmaceutical Manufacturers Association, Washington, D.C., 1993, p. 4. |
|
|
|
|
|